Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $4 | $2 | $2 | $2 |
| % Growth | 138.7% | -24.2% | 11.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $2 | $2 | $2 |
| % Margin | 98.3% | 96% | 96.5% | 96.1% |
| R&D Expenses | $9 | $6 | $12 | $6 |
| G&A Expenses | $3 | $3 | $3 | $2 |
| SG&A Expenses | $2 | $3 | $3 | $2 |
| Sales & Mktg Exp. | -$0 | $0 | -$0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $9 | $15 | $8 |
| Operating Income | -$7 | -$7 | -$13 | -$4 |
| % Margin | -184.9% | -466.2% | -612.8% | -236.8% |
| Other Income/Exp. Net | $2 | -$1 | -$2 | $0 |
| Pre-Tax Income | -$5 | -$9 | -$15 | -$4 |
| Tax Expense | $0 | -$2 | -$2 | -$2 |
| Net Income | -$5 | -$7 | -$13 | -$7 |
| % Margin | -129.8% | -446.7% | -595.5% | -342.4% |
| EPS | -0.42 | -0.84 | -1.2 | -1.56 |
| % Growth | 50% | 30% | 23.1% | – |
| EPS Diluted | -0.42 | -0.84 | -1.2 | -1.56 |
| Weighted Avg Shares Out | 12 | 9 | 11 | 4 |
| Weighted Avg Shares Out Dil | 12 | 9 | 11 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$8 | -$15 | -$8 |
| % Margin | -185.4% | -468.6% | -689.9% | -438.5% |